CytRx
Galena Biopharma late last month completed its spinout of RNAi drugs subsidiary RXi Pharmaceuticals, ending a year-long saga that included an acquisition, litigation, and a management shakeup that included the loss of RXi's CSO.
CytRx said it sold the shares for $7 million.
Although the suit was first filed last summer, the courtroom showdown had been brewing for years.
Nov 12, 2009
Jul 16, 2009